- Gemcitabine
- Bacillus Calmette-Guérin (BCG)
- Radical Cystectomy
- Transurethral Resection of Bladder Tumor (TURBT)
- Urologic Oncology
- Shared Decision-Making
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- 2025 NMIBC Creator Weekend™
- Bladder Cancer
When a patient is diagnosed with non-muscle invasive bladder cancer (NMIBC), how do you tailor the conversation and treatment plan to their individual needs (and fears)? In part two of the 2025 NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam is joined by Dr. Sima Porten from UCSF and Dr. Patrick Hensley from the University of Kentucky to discuss patient-centered diagnostic and therapeutic approaches for non-muscle invasive bladder cancer.
This podcast is supported by
Timestamps
Resources
More about this episode
The conversation covers initial patient consultations, discussing diagnoses, personalized treatment options such as BCG, gemcitabine, clinical trials, and managing side effects. The experts emphasize the importance of clear communication, understanding patient preferences, and tailoring approaches to enhance the patient's quality of life. They also explore insights from recent studies like the CISTO trial and highlight novel research directions.


